Seeking Alpha

Exelixis (EXEL) resumes trading after a long halt, now down 33.4% AH, after announcing it's...

Exelixis (EXEL) resumes trading after a long halt, now down 33.4% AH, after announcing it's initiating its first phase 3 trial of cabozantinib for patients with a particular type of prostate cancer. Without an agreement with the FDA, the company's not pursuing a special protocol assessment from the agency.
From other sites
Comments (2)
  • TruffelPig
    , contributor
    Comments (4077) | Send Message
     
    One should perhaps add that the same drug just tested excellent in another phase III trial. The discrepancies here have something to do with the lack of a good assessment of bone metastasis.
    31 Oct 2011, 06:01 PM Reply Like
  • TruffelPig
    , contributor
    Comments (4077) | Send Message
     
    I did read the press release careful again and have come to the conclusion that this is a overreaction of the market. EXEL did not want to wait longer for a certain endpoint definition by FDA, but went ahead to help those patients with bone metastasis in prostate cancer to live better quality (=pain reduced) lives. I am convinced that the drug will work great as in the other trial and the patients will live longer pain free or reduced. I bought some more at $5 in AH.

     

    LONG EXEL
    31 Oct 2011, 06:14 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs